Abbott Laboratories Launches ICRAS Tool to Help Doctors Assess Heart and Kidney Risks in Diabetes Patients

Managing diabetes is not only about controlling blood sugar. For millions of patients, the real danger lies in cardiovascular and kidney complications that develop over time.

To address this challenge, Abbott Laboratories has launched the International Cardio-Renal Risk Assessment and Stratification (ICRAS) Tool, a web-based platform designed to help doctors across India identify heart and kidney risks in people living with Type 2 Diabetes.

The goal is simple: detect risk earlier and improve patient outcomes.

Why Early Risk Assessment Matters in Diabetes?

India is often described as the diabetes capital of the world. Today, more than 101 million people in the country are living with diabetes, according to recent estimates.

For many patients, diabetes eventually leads to serious complications such as:

• Diabetic Kidney Disease (DKD)
• Coronary Heart Disease (CHD)
• Major Adverse Cardiovascular Events (MACE)

These complications are among the leading causes of morbidity and mortality in people with type 2 diabetes. Early identification of risk factors can help clinicians intervene sooner and reduce long-term damage.

What the ICRAS Tool Does?

The ICRAS Tool is designed to support clinicians in assessing cardio-renal risk among diabetic patients.

The platform combines several clinical indicators and lifestyle factors to generate separate risk scores for:

• Kidney disease risk
• Heart disease risk
• Major cardiovascular event risk

Key features of the tool include:

• Integration of medical test results and patient health indicators
• Gender-specific risk assessment for more personalized evaluation
• Clear risk summaries to support clinical decision-making

This approach helps doctors quickly identify high-risk patients who may require earlier intervention.

Developed with Guidance from Diabetes Experts

The ICRAS Tool was developed with input from a panel of leading medical experts.

Contributors include specialists such as:

• Sanjay Kalra
• V Mohan
• Atul Dhingra
• Deep Dutta
• Dinesh Khullar
• Jothydev Kesavadev
• K D Modi
• Manash P Baruah
• Nitin Kapoor
• Pramila Kalra
• Shehla Shaikh
• Tiny Nair

Their guidance helped shape the tool’s clinical framework for assessing cardio-renal complications in diabetes.

Supporting Better Clinical Decisions

According to Kartik Peethambaran, Medical Director at Abbott India, the initiative aims to strengthen patient evaluation and screening.

He noted that the tool enables clinicians to:

• Assess a patient’s likelihood of developing diabetic kidney disease
• Identify risks of coronary heart disease
• Evaluate chances of major cardiovascular events

By providing data-driven insights, the tool helps doctors make timely and evidence-based treatment decisions.

Built with Privacy in Mind

Another key aspect of the platform is data security. The web-based ICRAS Tool:

• Does not capture personal information from patients
• Does not store doctor-specific data
• Ensures assessments remain fully secure and confidential

This allows healthcare professionals to use the tool confidently during patient evaluations.

The Bigger Picture

With diabetes cases rising rapidly in India, healthcare systems are increasingly focusing on preventing long-term complications rather than treating them after they appear.

Digital clinical tools like the ICRAS Tool could play an important role in:

• Improving early detection of cardio-renal risks
• Supporting preventive care strategies
• Enhancing clinical decision-making in diabetes management

For doctors managing large diabetic populations, such tools may become a valuable addition to routine care.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!